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IMPs, also known as insulin-like growth factor 2 (IGF2)
messenger RNA (mRNA)-binding proteins (IGF2BPs),
are highly conserved oncofetal RNA-binding proteins
(RBPs) that regulate RNA processing at several levels, in-
cluding localization, translation, and stability. Three
mammalian IMP paralogs (IMP1–3) have been identified
that are expressed in most organs during embryogenesis,
where they are believed to play an important role in cell
migration, metabolism, and stem cell renewal. Whereas
some IMP2 expression is retained in several adult mouse
organs, IMP1 and IMP3 are either absent or expressed at
very low levels in most tissues after birth. However, all
three paralogs can be re-expressed upon malignant trans-
formation and are found in a broad range of cancer types
where their expression often correlates with poor progno-
sis. IMPs appear to resume their physiological functions
in malignant cells, which not only contribute to tumor
progression but participate in the establishment and
maintenance of tumor cell hierarchies. This review sum-
marizes our current understanding of the functions of
IMPs during normal development and focuses on a series
of recent observations that have provided new insight into
how their physiological functions enable IMPs to play a
potentially key role in cancer stem cell maintenance
and tumor growth.
RNA-binding proteins (RBPs) regulate gene expression by
intervening at all stages of messenger RNA (mRNA) me-
tabolism, including transcription, 5′ end capping, precur-
sor mRNA splicing, 3′ end processing, nuclear export,
transport, translation, and stability (for review, see Mul-
ler-McNicoll and Neugebauer 2013). Individual RBPs
may have asmany as hundreds to thousands ofmRNA tar-
gets (Hafner et al. 2010; Anko and Neugebauer 2012;
Ascano et al. 2012) and serve as structural components
of messenger ribonucleoprotein particles (mRNPs), in
which mRNAs are transported from the nucleus to the
cytoplasm and whose composition helps determine
transcript fate (Muller-McNicoll and Neugebauer 2013).
As many RBPs lack enzymatic activity, they can exert
some of their regulatory functions by recruiting additional
proteins, which may include decay enzymes and transla-
tional repressors (Moore and Proudfoot 2009; Schoenberg
and Maquat 2012). RBPs thereby not only add to the
structural and functional diversity of mRNPs but, more
importantly, orchestrate the composition of RNA pro-
cessing effector complexes to which they confer sequence
specificity.
RBPs share post-transcriptional regulation of mRNA
stabilitywithmicroRNAs (miRNAs), 21- to 22-nucleotide
(nt) noncoding RNAs (ncRNAs) that mediate post-
transcriptional silencing by target mRNA degradation or
translational repression (Bartel 2009) and are implicated
in the regulation of virtually all biological processes in
multicellular organisms (He and Hannon 2004; Ivey and
Srivastava 2010). miRNA biogenesis is a multistep pro-
cess that is not discussed here, and we refer readers to sev-
eral excellent reviews (Ha and Kim 2014; Lin and Gregory
2015).
MiRNAs and RBPs can exert synergistic or opposing
effects on target mRNAs (for review, see van Kouwen-
hove et al. 2011; Ciafre andGalardi 2013; Ho andMarsden
2014). RBPs can cooperate with miRNAs to effect mRNA
destabilization by recruiting miRNA-containing RNA-
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induced silencing complexes (RISCs), the core of which
consists of Argonaute proteins (AGO1–4) (for review, see
Ha and Kim 2014), to target mRNAs (Jing et al. 2005;
Kim et al. 2009; Glorian et al. 2011) or altering the second-
ary structure of target mRNAs to render miRNA-binding
sites more accessible (Kedde et al. 2010). Conversely,
RBPs can compete with miRNAs for binding to or in
the vicinity of miRNA recognition binding sites (also
referred to as miRNA recognition elements [MREs]) on
target mRNAs, including their own, and protect tran-
scripts from miRNA-dependent degradation (Kedde et al.
2007; Kundu et al. 2012; Young et al. 2012; Xue et al.
2013). In some situations, the same RBP can exert a
stabilizing or destabilizing effect on different target
mRNAs, depending on its interplay with miRNAs that
associate with the same transcripts (Srikantan et al.
2012). Determination of mRNA fate by this complex
relationship between RBPs and miRNAs affects a broad
panel of physiological and pathological events from
embryogenesis and differentiation to transformation
and tumorigenesis.
Among the ∼600 RBPs annotated in mammalian ge-
nomes based on their content of knownRBPs and 800 can-
didate RBPs identified in cell lines using new high-
throughput ultraviolet (UV) cross-linking technologies
(Baltz et al. 2012; Castello et al. 2012), relatively few
have been associated with cancer. RBPs with a recognized
role in tumor growth and progression include the TET
family (Riggi et al. 2007), the STAR family (Elliott and
Rajan 2010), β-catenin (Lee et al. 2007; Kim et al. 2012),
LIN28A and LIN28B (Viswanathan et al. 2009; Nguyen
et al. 2014), and several RBPs involved in RNA splicing
(David and Manley 2010). Recent work from several labo-
ratories has shown that the IMP family of oncofetal RBPs
can promote carcinogenesis in part by regulating miRNA
activity.
Three mammalian IMP paralogs—IMP1–3, also known
as insulin-like growth factor 2 (IGF2) mRNA-binding pro-
teins 1, 2, and 3 (IGF2BP1–3)—have been identified thus
far. They belong to the family of zipcode-binding proteins
initially proposed to bear the acronym VICKZ based on
the first letter of its foundingmembers (Yaniv and Yisraeli
2002), which include Vegetal-1 mRNA-binding protein
(Vg1RBP/Vera) in Xenopus laevis; IMP1–3 in mammals;
coding region instability determinant (CRD)-binding pro-
tein, subsequently shown to be IMP1; K homology
(KH) domain-containing protein overexpressed in cancer
(KOC), subsequently shown to be IMP3; and zipcode-bind-
ing protein 1 (ZBP1) in chickens. ZBP1 was shown to bind
a 54-nt sequence element (or zipcode) located in the 3′ un-
translated region (UTR) of β-actinmRNA in chicken cells,
which resulted in the active transport of β-actin tran-
scripts to regions of polarized cell growth in neurons and
fibroblasts (Ross et al. 1997; Bassell et al. 1999; Farina
et al. 2003; Huttelmaier et al. 2005). IMP1 (a ZBP1 ortho-
log) was identified as a protein involved in MYC mRNA
stabilization (Doyle et al. 1998). Its mechanism of action
was shown to be prevention of MYC degradation by bind-
ing to its CRD (hence the initial denominationCRD-bind-
ing protein). Similar to ZBP1 in chicken cells, IMP1 was
observed to control the subcellular localization of β-actin
mRNA in primary mammalian fibroblasts (Farina et al.
2003) and neurons (Tiruchinapalli et al. 2003) by binding
to the cis-acting zipcode in the 3′ UTR. Human IMP2,
which has diverged phylogenetically from IMP1 and
IMP3 and has no known orthologs, was discovered as a re-
sult of its binding to IGF2 transcripts (Nielsen et al. 1999).
It was also referred to as p62, reflecting the molecular
mass of one of its splice variants, and was proposed to be
an autoantigen in hepatocellular carcinoma (HCC) (Zhang
et al. 1999a). Single-nucleotide polymorphisms (SNPs)
have been identified in the second intron of the IMP2
gene that correlate with elevated risk of type 2 diabetes
(Christiansen et al. 2009). IMP3, a Vg1-RBP/Vera ortholog
initially called KOC, was identified on the basis of its
abundance in pancreatic cancer (Mueller-Pillasch et al.
1997). It was subsequently shown to be expressed by a
broad range of tumors, and its expression was often found
to correlate with poor prognosis (for review, see Lederer
et al. 2014).
Physiological expression of IMP family members
Physiological expression of IMPs occurs primarily during
development.Mammalian IMPs display a biphasic expres-
sion pattern, first appearing in the oocyte and zygote (Niel-
sen et al. 2001; Yaniv and Yisraeli 2002) and subsequently
displaying up-regulation on mouse embryonic day 10.5
(E10.5) to E12.5 (Nielsen et al. 1999; Runge et al. 2000).
At mid-gestation, IMPs are expressed in most developing
tissues, their expression being highest in neuronal and
epithelial cells. Imp1 and Imp3 transcripts are expressed
in the forebrain and hindbrain, the snout, the branchial
arches, the gut, the tail, the vertebrae, and the skin (Muel-
ler-Pillasch et al. 1999; Mori et al. 2001; Hansen et al.
2004). A similar expression pattern is observed in Xeno-
pus, zebrafish, and Drosophila (Mueller-Pillasch et al.
1999; Zhang et al. 1999b; Nielsen et al. 2000; Adolph
et al. 2009). Detailed assessment of expression in mouse
brains revealed that, at E10.5, Imp1 is expressed through-
out the ventricular zone (VZ) of the entire developing brain
with the exception of the floor and roof plates. Between
E12.5 and E16.5, Imp1 expression gradually becomes
restricted primarily to the dorsomedial telencephalon
(DMT), where it continues to be expressed by undifferen-
tiated neural stem/progenitor cells in the VZ and sub-VZ
(SVZ) (Nishino et al. 2013). Little or no Imp1 expression
is observed in differentiated neurons that accumulate
at the cortical plate, and virtually no Imp1 expression
remains in the cerebral cortex at birth. However, some
Imp1 expression persists in the small and large intestines,
kidney, and liver for several days after birth, and low Imp1
expression levels can be detected in the intestines of
adult mice (Hansen et al. 2004). In contrast to Imp1,
Imp3mRNA becomes virtually undetectable at birth.
During embryogenesis, Imp2 expression resembles that
of Imp1 and Imp3 (Christiansenet al. 2009) and, atE17.5, is
observed in thebrain—including theneopallial cortex,VZ,
and striatum—as well as the nasal cavity, lungs, liver,
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intestines, and kidney. However, unlike Imp1 and Imp3,
Imp2 transcripts are prominent in the perinatal period
and in adultmouse tissues, including brain, gut, bonemar-
row, kidney, lung, muscle, liver, testis, and pancreas (Bell
et al. 2013). Thus, IMP2 expression overlaps with that of
IMP1 and IMP3 during development but, in contrast to
that of its paralogs, persists in several adult organs inmice.
Protein structure and RNA binding
Inmammals, the canonical structure of the three IMP pro-
teins is highly similar in terms of domain order and spac-
ing (Fig. 1). The overall amino acid sequence identity
between the three proteins is 56% (Bell et al. 2013), with
even greater similarity within the domains, consistent
with shared functions. IMP1 and IMP3 are themost close-
ly related members of the family, with 73% amino acid
sequence identity (Bell et al. 2013). All three proteins
contain two RNA recognition motifs (RRMs) in their
N-terminal regions and four hnRNP KH domains in their
C-terminal regions (Nielsen et al. 1999). In Drosophila, a
protein lacking the N-terminal RRM domain but con-
taining four KH domains is proposed to be theDrosophila
IMP (dIMP) (Bell et al. 2013).
All members of the IMP family, irrespective of the or-
ganism in which they are expressed, have been shown to
bind RNA. In vitro studies have shown that the KH do-
mains are primarily responsible for RNA binding, al-
though the RRMs may contribute to the stabilization of
IMP–mRNA complexes (Nielsen et al. 2004; Wachter
et al. 2013). However, the architecture of the KH domains
allows recognition of only short stretches of RNA with
relatively weak binding affinity (Chao et al. 2010) that
may be insufficient for appropriate regulation of target
mRNA fate. Increased binding affinity and specificity
are typically achieved by the presence of multiple copies
of these domains within the RBP along with their arrange-
ment in an orientation that optimizes interaction with
their partners. Structural analyses of IMP1 KH domains
3 and 4 suggest that they function as a single module by
assuming an anti-parallel pseudodimer conformation in
which the RNA-binding surfaces are placed on opposite
ends of the molecule (Chao et al. 2010). The RBP can
therefore recognize its targets through sequence-specific
interactions that span two stretches of RNA separated
by an appropriate number of nucleotides (Chao et al.
2010). Two low-affinity interactions can thereby generate
highly specific RNA binding, suggesting that IMPs may
force their associated transcripts to adopt a specific con-
formation. Based on this notion, a model has been pro-
posed in which binding of KH3 and KH4 to mRNA
induces a conformational change in the transcript (Chao
et al. 2010), which may create new RNA-binding sites
for other factors. The IMP family of RBPs may therefore
orchestrate the assembly of higher-order complexes,
which may not necessarily require direct interaction
with other proteins (Chao et al. 2010). The long half-life
of IMP–mRNA complexes in vitro testifies to their stabil-
ity and supports the notion that IMPs bind their target
mRNAs with high affinity (Nielsen et al. 2004).
The mRNA-binding repertoire of IMP family members,
which should provide insight into the mechanisms by
which they regulate transcript processing and the corre-
sponding cellular functions, is beginning to be elucidated.
A genome-wide study in HEK293T cells using photoacti-
vatable ribonucleoside-enhanced UV cross-linking and
immunoprecipitation (PAR-CLIP), which provides an al-
most single-nucleotide resolution of RNA-binding sites,
proposed the definition of a putative IMP consensus recog-
nition element as 5′-CAUH-3′ (H =A, U, or C) (Hafner
et al. 2010). The candidate recognition element was con-
tained in >75% of the top 1000 clusters for IMP1–3 and
identified >100,000 sequence clusters recognized by the
IMP family that map to ∼8400 protein-coding transcripts
(Hafner et al. 2010). A more recent comparison of IMP
Figure 1. Structure of IMP paralogs. (Top) Amino acid sequence alignment and corresponding domain structure of IMP1, IMP2, and
IMP3. Sequence similarity among the paralogs is highlighted in red, and colors indicate the boundaries of the domains shown in B. Num-
bers represent corresponding base numbers of the respective genes. (Bottom) Schematic representation of IMP domains.
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RNA-binding specificity using enhancedUVCLIP (eCLIP)
in human pluripotent stem cells (hPSCs), which express
all three paralogs, revealed significant overlap between
IMP1 and IMP2 binding that was not observed between ei-
ther IMP1 and IMP3 or IMP2 and IMP3 (Conway et al.
2016). IMP1 and IMP2 were found to bind predominantly
3′ UTRs of target genes with enrichment of CA motifs in
eCLIP-defined binding sites, whereas IMP3 bound a high-
er portion of coding regions, which did not correlate with
either IMP1 or IMP2 (Conway et al. 2016).
PAR-CLIP applied to a primary proneural glioblastoma
(GBM) grown as a glioma stem cell (GSC)-enriched spher-
oid culture and its nontumorigenic adherent progeny
(Degrauwe et al. 2016) revealed that IMP2 preferentially
localizes to 3′ UTRs of target mRNAs with high AT con-
tent and miRNA-binding sites. IMP2-binding density was
enriched on a subset of miRNA-binding sites, suggesting
that IMP2 protects these transcripts from miRNA-medi-
ated silencing. Consistent with this notion, transcripts
bound by IMP2 onmiRNA-binding sites of previously val-
idated miRNA targets constituted the class of mRNAs
that was the most strongly silenced upon IMP2 depletion
(Degrauwe et al. 2016).
Physiological functions
Several approaches, including reverse genetics in loss-of-
function and gain-of-function models, have been used to
address the physiological role of IMPs. In Drosophila, ab-
errant expression of neuronal dIMP resulted in compro-
mised central and peripheral synaptogenesis, suggesting
that dIMP is required for appropriate exon guidance, sim-
ilar to IMP1 in mammalian cells (Boylan et al. 2008). In
Xenopus, depletion of Vg1RBP/Vera revealed its require-
ment for migration of cells from the roof plate of the neu-
ral tube and for neural crest migration (Yaniv et al. 2003).
These observations are consistent with the well-estab-
lished function of IMP1 in mRNA localization, as illus-
trated by IMP1-mediated and neuronal ZBP1-mediated
β-actinmRNA transport to the leading edge of migrating
fibroblasts (Farina et al. 2003) and to dendrites and growth
cones (Zhang et al. 2001; Tiruchinapalli et al. 2003), re-
spectively. Based on these observations, IMP1 has been
proposed to enhance neurite outgrowth and axonal guid-
ance. Additional mRNAs whose localization is shown to
be regulated by IMP1 include H19 and Tau (Runge et al.
2000; Atlas et al. 2004). The full repertoire of mRNAs sub-
jected to IMP1-mediated transport remains to be deter-
mined but is likely to be extensive, as suggested by a
study that found 3% of the transcriptomes of HEK293
cells to be represented in IMP1 mRNP granules (Jonson
et al. 2007). The most abundant of these transcripts
encode proteins implicated in the secretory pathway,
ubiquitin-dependent protein degradation, and post-tran-
scriptional control of mRNA processing and translation.
The degree to which IMP2 and IMP3 participate in RNA
localization remains to be elucidated.
Gene deletion experiments indicate additional physio-
logical functions. IMP1-deficient mice are ∼40% smaller
than normal sex-matched littermates, with proportional
reduction in the size ofmost organs, and are subject to sig-
nificant perinatal mortality, attributed primarily to de-
fects in intestinal development (Hansen et al. 2004).
Histological changes in the gut among Imp1−/− mice
range from an almost normal appearance to nearly com-
plete loss of villi, decreased mucosal and muscle wall
thickness, and modifications of the composition of the
intestinal extracellular matrix (Hansen et al. 2004). In sur-
vivingmice, the histologicalmodifications become gradu-
ally normalized, suggesting that Imp1 deficiency may
cause delayed organ maturation (Hansen et al. 2004). To-
gether, these observations raise the possibility that
IMP1 may be implicated in the regulation of cell metabo-
lism and/or stem cell maintenance.
Consistent with this notion, recent work suggests that
IMP1 regulates changes in stem cell properties in fetal
brains (Nishino et al. 2013). Imp1 was found to be ex-
pressed by fetal neural stem/progenitor cells in response
to Wnt signaling, and the decline in its expression in
late fetal development was observed to occur partly as a
consequence of let-7 miRNA expression, of which Imp1
is a target (Nishino et al. 2013). Upon Imp1 deletion, fetal
neural stem cells (NSCs) became prematurely depleted in
the dorsal telencephalon due to accelerated differentia-
tion, resulting in impaired pallial expansion and reduced
brain mass. Based on these observations, Imp1 expression
by stem/progenitor cells during forebrain development
was proposed to regulate the timing of neuronal and glial
differentiation, and postnatal loss of its expression was
suggested to contribute to the decline in NSC function
during adulthood (Nishino et al. 2013). Imp1 therefore ap-
pears to be required for the expansion of fetal NSCs but
dispensable for self-renewal of adult NSCs. Taken togeth-
er, these observations suggest that Imp1 may belong to a
heterochronic gene network that regulates temporal
changes in stem cell properties from fetal development
throughout adulthood (Nishino et al. 2013). In addition
to regulating NSC expansion, IMP1 may influence other
stem cell functions. Thus, in hPSCs, IMP1 has been
shown recently to regulate adhesion and promote survival
(Conway et al. 2016).
Given that IMP2 is highly expressed in developing
brains (with a peak around mid-gestation in mice)
(Nielsen et al. 1999) and that its depletion in NSCs
favors astrocytic lineage commitment (Fujii et al. 2013),
it would seem plausible that, similar to IMP1, IMP2
may participate in NSC/progenitor cell maintenance.
Using conditional Imp2 knockout mice crossed to Nestin
Cre animals, Imp2 depletion was shown to impair NSC
clonogenicity. Consistent with the observations of Fuji
et al. (2013), NSCs depleted of Imp2 displayed increased
glial and reduced neuronal differentiation (Degrauwe
et al. 2016).
The phenotype of mice bearing homozygous Imp2 dele-
tion suggests that IMP2may play an important role in the
control of cell metabolism. Imp2-deficientmice displayed
a slightly smaller size than their normal littermates,
which corresponded to mildly reduced linear growth and
lean mass gain after weaning as well as decreased fat
Degrauwe et al.
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deposition following a high-fat diet with a decrease in ad-
ipocyte precursors (Dai et al. 2015). In addition, these
mice displayed modestly increased energy expenditure,
improved glucose tolerance, resistance to the develop-
ment of fatty liver, and a longer life span than their
wild-type littermates (Dai et al. 2015). IMP2 was discov-
ered to bind uncoupling protein-1 (Ucp1) mRNA along
with transcripts of several other mitochondrial proteins
and inhibit its translation. The increased energy expendi-
ture of Imp2−/−mice was proposed to be a consequence of
increasedUCP1 expression and contribute to resistance to
obesity and the observed increased life span (Dai et al.
2015). Consistent with the phenotype of Imp2−/− mice,
transgenic overexpression of Imp2 in mouse livers result-
ed in steatosis (Tybl et al. 2011). Interestingly, one of the
first SNPs found by a genome-wide association study
(GWAS) for type 2 diabetes mellitus (T2DM) is located
in intron 2 of IMP2 (Diabetes Genetics Initiative of Broad
Institute of Harvard and MIT, Lund University, and
Novartis Institutes of BioMedical Research 2007; Scott
et al. 2007; Zeggini et al. 2007). However, the molecular
mechanisms that may implicate IMP2 in T2DM remain
to be uncovered.
IMP2 has also been shown to play a role in muscle cell
motility (Boudoukha et al. 2010). IMP2 expressionwas ob-
served to be elevated in primarymyoblasts, myogenic cell
lines, and regenerating skeletal muscle (Boudoukha et al.
2010). Its depletion resulted in a change in muscle cell
shape and a decrease in motility. Whereas it would seem
reasonable to assume that, by analogy to the function of
IMP1, the observed changes may be related to alterations
in β-actin or other cytoskeletal component mRNA trans-
port, analysis of IMP2-depleted muscle cells revealed al-
terations in post-translationally modified α-tubulin
associated with stable, nondynamic microtubules (Bou-
doukha et al. 2010).
The effects of IMP3 depletion in the organism remain to
be determined, as there are currently no available knock-
out models.
Mechanisms of action
Evidence thus far indicates that IMP family members reg-
ulate a broad range of RNA processing steps, including lo-
calization, stability, translation, and possibly nuclear
export (Nielsen et al. 2001; Yaniv and Yisraeli 2002; Bell
et al. 2013). IMPs are primarily cytoplasmic, but the pres-
ence of two nuclear export signals suggests that they may
bind at least some of their target RNAs in the nucleus
and possibly facilitate their nuclear export (Oleynikov
and Singer 2003; Huttelmaier et al. 2005; Pan et al. 2007).
In the cytoplasm, IMPs form higher-order mRNP struc-
tures, which are large enough to be visible under the light
microscope and therefore are referred to asmRNPgranules
(Mitchell and Parker 2014). IMPmRNP granules are locat-
ed around the nucleus and in cell protrusions. In neuronal
cells, these granules localize todendrites andgrowthcones
(Zhang et al. 2001; Tiruchinapalli et al. 2003), consistent
with the notion that they are destined for local translation.
IMP1-containing RNP granules are distributed along mi-
crotubules and are reported to travel toward the leading
edge ofmotile cells into the cortical region of lamellipodia
at an average of 0.12 µm/sec in an ATP-dependent fashion
(Nielsenetal. 2002). IMP1granules aresuggested toconsti-
tute auniquemRNPentitydistinct fromprocessingbodies
(P bodies), stress granules, and neuronal hStaufen granules
(Jonson et al. 2007), although possibly related to RNA
transport granules, which are prevalent in neurons and oo-
cytes and are suggested to play a role in RNA localization
(for review, seeMitchell and Parker 2014). They are report-
ed to be 100–300 nm in diameter and, in addition to IMPs
(IMP1 or IMP3), contain 40S ribosomal subunits, shuttling
hnRNPs, poly(A)-binding proteins, andmRNAs.Theyalso
containCBP80 and factors belonging to the exon–junction
complex but lack eIF4E and eIF4Gaswell as 60S ribosomal
subunits, suggesting that the constituent transcripts are
not translated (Jonson et al. 2007; Weidensdorfer et al.
2009). IMP1 may therefore regulate mRNA localization
by incorporating its target transcripts intomRNPgranules
that provide protection from premature degradation and
promiscuous translation and unloading them to initiate
protein synthesis at appropriate destinations.
Similar to other RBPs, IMP1 regulates the expression of
numerous proteins, increasing the levels of some by aug-
menting the stability of their mRNAs and reducing the
levels of others by inhibiting translation (for review, see
Bell et al. 2013). Several recent studies have shown that
one mechanism by which IMPs promote mRNA stability
is by preventing miRNA-mediated silencing (Elcheva et
al. 2009; Goswami et al. 2010; Nishino et al. 2013; Busch
et al. 2016; Degrauwe et al. 2016). IMP1 was notably ob-
served to promote the expression of the self-renewal factor
and let-7 miRNA family target HMGA2 (for review, see
Fusco and Fedele 2007), which raised the possibility that
IMP1 may counteract let-7 miRNA action during
development and thereby contribute to stem cell mainte-
nance (Nishino et al. 2013). let-7 is a highly evolutionarily
conserved 13-member family of miRNAs that promotes
differentiation and suppresses tumor growth (Pasquinelli
et al. 2000). Several let-7 target gene products—including
LIN28A, LIN28B, and HMGA2—display both self-renew-
al and oncogenic functions, and LIN28A/B control let-7-
mediated differentiation. LIN28 RBP paralogs, which are
expressed in embryonic stem cells (ESCs), progenitor
cells, and primordial germ cells (Moss and Tang 2003;
West et al. 2009; Viswanathan and Daley 2010; Shyh-
Chang and Daley 2013), maintain let-7 expression at low
levels by blocking let-7 biogenesis, preventing their tran-
sition from the pre-miRNA to the mature miRNA form
(Heo et al. 2008, 2009; Shyh-Chang and Daley 2013).
LIN28A/B and let-7 thereby form a bistable switch that
operates to maintain stemness or induce differentiation
(for review, see Thornton and Gregory 2012). In the brain,
NSC maintenance and differentiation (Nishino et al.
2008; Yu et al. 2015) as well as glial progenitor cell differ-
entiation to astrocytes (Shenoy et al. 2015) are regulated
by let-7 family members and their targets.
Sequestration of miRNA target mRNAs inmRNP gran-
ules that are free of Ago/RISC (Weidensdorfer et al. 2009;
IMPs link normal and cancer stem cell maintenance
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Busch et al. 2016) is proposed to be one mechanism
by which IMP1 protects mRNAs from let-7-mediated si-
lencing (Fig. 2). However, IMP1 has also been observed
to disrupt miRNA-183-mediated targeting of the coding
region of β-transducin repeat-containing E3 ubiquitin pro-
tein ligase (BTRC) transcripts (Elcheva et al. 2009) and
miRNA-340-mediated targeting of the 3′ UTR of micro-
phthalmia-induced transcription factor (MITF) mRNA
(Goswami et al. 2015). IMP1 thus appears to protect its
target mRNAs by at least two mechanisms by prevent-
ingmiRNA binding to its recognition sites and/or displac-
ing miRNA-containing RISCs and incorporating target
mRNAs into mRNP, where they may be stored while
awaiting release toward their ultimate fate (Fig. 2). The
latter mechanismmay help fine-tune the timing of specif-
ic transcript translation or decay.
IMP3 has been proposed to function in a way similar to
that of IMP1, sequestering LIN28B, HMGA2 transcripts,
and mRNAs of several other let-7 target genes into cyto-
plasmic granules that do not contain RISC/Ago (Fig. 2;
Jonson et al. 2014). These IMP3 mRNP granules have
been proposed to function as “cytoplasmic safe houses”
for a variety of oncogenes and stemness maintenance
genes targeted bymiRNAs, particularly let-7 familymem-
bers. Whether IMP3-associated mRNP granules have the
same composition as their IMP1-associated counterparts
remains to be determined. However, IMP1 and IMP3
have been observed in the same mRNP granules (Jonson
et al. 2007), suggesting that the two RBPs share at least a
fraction of their mRNPs. IMP3 and let-7 family members
are reported to bind 3′ UTRs of target mRNAs in close
proximity to each other (Jonson et al. 2014), but the bind-
ing appears to occur simultaneously without competition
for a common binding site. Sequestration into AGO2/
RISC-free mRNP granules may therefore be the principal
mechanismof IMP3-mediatedmRNAprotection from let-
7-dependent silencing. In contrast, in pancreatic ductal ad-
enocarcinoma cells (PDACs), IMP3 was reported to com-
pete with miRNAs for common binding sites in target
mRNA 3′ UTRs but also promote association of mRNAs
with AGO2/RISC, suggesting a function as a bimodal reg-
ulator of target mRNA stability (Ennajdaoui et al. 2016).
Taken together, these observations suggest that IMP1
and IMP3may regulatemRNAstability bymultiplemech-
anisms, including sequestration in RISC-freemRNP gran-
ules, protection from miRNA-dependent degradation by
competing for common binding sites, and enhancement
of degradation by recruitment of AGO2/RISC to target
mRNAs. Whereas the repertoire of effects that IMP1 and
IMP3 may have on target mRNAs is becoming relatively
clear, the underlying mechanics require further elucida-
tion. By what mechanism is AGO/RISC excluded from
IMP1 and IMP3 mRNP granules? What determines re-
cruitment of AGO/RISC to some IMP3 target transcripts
but not others? Furthermore, is there selectivity as to
which mRNAs are incorporated into the AGO/RISC-free
mRNPs, or are all IMP1 and IMP3 target transcripts in-
cluded regardless of whether the IMPs have disrupted
miRNA-mediated silencing by binding to the same cis-el-
ements or in their immediate vicinity? The availability of
genome-widemRNA-binding repertoires of the IMP fami-
ly should help address these issues.
IMP2 protects mRNAs from let-7-dependent silencing
by binding to the corresponding miRNA-binding sites
and preventing miRNA-mediated target transcript degra-
dation (Fig. 2; Degrauwe et al. 2016). In contrast to IMP1
and IMP3, IMP2 was observed in P bodies, the assembly
of which is dependent on the pool of nontranslating
mRNA and which contain the conserved core of proteins
implicated in mRNA decay and translation repression
(Decker and Parker 2012; Lui et al. 2014; Anderson et al.
2015) However, mRNA decay itself does not necessarily
occur within the bodies, and, in mammalian cells,
mRNAs in P bodies can return to translation (Brengues
et al. 2005; Anderson and Kedersha 2006; Bhattacharyya
et al. 2006). How incorporation into P bodies might in-
fluence the fate of IMP2-bound mRNAs is currently un-
clear. Coimmunoprecipitation experiments uncovered a
RNA-dependent association between AGO2 and IMP2
(Degrauwe et al. 2016) whose significance, in light of the
maintained expression of let-7 target genes, remains enig-
matic. It is conceivable that the interaction has an inhib-
itory effect on AGO2/RISC, but such a possibility has not
been addressed directly.
The repertoire of mRNAs whose stability is regulated
by IMPs may predict, at least in part, the phenotype of
IMP paralog-expressing cells. Thus, protection of BCL2
and integrin transcripts, particularly ITGB5, by IMP3
has been reported recently to promote survival and adhe-
sion, respectively, in hPSCs (Conway et al. 2016).Whether
these effects are related to protection from let-7 or other
miRNAs remains to be determined. Enforced expression
of IMP3 in the murine hematopoietic system resulted in
increased numbers of hematopoietic stem cells (HSCs),
Figure 2. Mechanisms ofmRNAprotection frommiRNA-medi-
ated silencing by IMPs. Whereas LIN28A/B impair let-7 miRNAs
maturation, IMP2 prevents let-7 target gene silencing by direct
binding to let-7 MREs on mRNAs. IMP2 is found in P bodies,
where it may be in direct competition with AGO2, the catalytic
component of the RISC. Although IMP1 and IMP3may also bind
to MREs or in their immediate vicinity, safe-housing transcripts
in a RISC-free environment constituted of mRNP granules is cur-
rently the best-understood mechanism by which they protect
their target mRNAs.
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lymphoid-primed multipotent progenitors (LMPPs), and
common lymphoid progenitors (CLPs) in the bone mar-
row, with increased proliferation of HSCs and LMPPs (Pal-
anichamy et al. 2016). Mouse hematopoiesis was skewed
toward the myeloid and B-cell lineages accompanied by
leukocytosis in the peripheral blood, atypical infiltration
of B cells into the thymic medulla, and increased myeloid
cell numbers in the spleen (Palanichamy et al. 2016). The
observed phenotype was ascribed to stabilization of Myc
and Cdk6 mRNAs by IMP3 based on individual nucleo-
tide-resolution CLIP (iCLIP) analysis and reporter assays.
However, the mechanism of the stabilization remains to
be elucidated, as deletion of single IMP3-binding sites in
the 3′ UTRs ofMyc and Cdk6 failed to reverse the pheno-
type of the reporter assays (Palanichamy et al. 2016).
Post-translational modifications of IMPs appear to be
essential for their modulation of mRNA fate. Thus, Src-
dependent phosphorylation of the linker region between
KH domains 2 and 3 of IMP1 is proposed to induce the dis-
assembly of cytoplasmic mRNPs and activate translation
of β-actin mRNA (Huttelmaier et al. 2005). Phosphoryla-
tion of Vg1RBP/Vera by MAPKs is suggested to modulate
the release of Vg1 mRNA from mRNPs localized to
the vegetal cortex during meiotic maturation (Git et al.
2009). Dual phosphorylation of IMP2 in the N-terminal
linker region between RRM2 and KH1 bymTOR complex
1 in a rapamycin-sensitive manner promotes its associa-
tion with the leader 3 (L3) 5′ UTR of IGF2 and the transla-
tional initiation of the mRNA through eIF4E and 5′ cap-
independent internal ribosomal entry, resulting in elevat-
ed IGF2 protein synthesis (Dai et al. 2011).
Althoughmost studies thus far have focused on interac-
tions of RBPs with coding transcripts, recent work has un-
covered interactions between IMPs and ncRNAs. Thus,
interaction of IMP2 with the long ncRNA (lncRNA)
MyoD was found to prevent translation of its associated
transcripts, N-Ras and C-myc (Gong et al. 2015). A study
conducted on mesenchymal GBM showed that IMP2 in-
teracts with the hypoxia-sensitive lncRNA HIF1a-AS2
and facilitates its association with its target transcripts,
such as HMGA1 (Mineo et al. 2016). IMPs also appear to
have the potential to destabilize lncRNAs, as shown by
the ability of IMP1 to recruit theCCR4–NOTdeadenylase
complex to degrade the liver-specific lncRNA HULC
(Hammerle et al. 2013).
Regulation of IMP expression
Most studies on IMP family members have focused on ex-
pression patterns during development andmechanisms of
action, and comparatively little is known about the regu-
lation of their expression. Nevertheless, there is evidence
to suggest that IMP1 expression is subject to regulation by
the Wnt pathway (Noubissi et al. 2006; Gu et al. 2008;
Nishino et al. 2013). In 293T cells, IMP1 could be induced
by β-catenin in a TCF-dependent manner (Noubissi et al.
2006). This was also observed to be the case in human
breast cancer cells (Gu et al. 2008), where β-catenin was
shown to bind to the IMP1 promoter and transactivate
the gene. IMP1 expression in mammalian breast cancer
cells correlated with nuclear translocation of endogenous
β-catenin, and a highly conserved element (CTTTG-TC)
located in the IMP1 promoter was shown to be necessary
for β-catenin-mediated regulation of IMP1 gene expres-
sion. IMP1 was observed to stabilize β-catenin mRNA,
suggesting a positive feedback loop in which β-catenin
and IMP1 regulate each other’s expression (Gu et al. 2008).
There is also evidence to suggest that IMP1 expression is
regulated by c-Myc (Noubissi et al. 2010). The human
IMP1 gene contains four consensus c-Myc-binding se-
quences in its promoter region. Both c-Myc and Max
were shown to interact with DNA fragments of the IMP1
promoter containing each of the four sites; mutagenesis
and reporter assays revealed that each c-Myc-binding site
contributes to the regulation of IMP1 transcription, and a
significant increase in IMP1 transcript and protein expres-
sion was observed in 293T and HeLa cells engineered to
overexpress c-Myc. Thus, c-Myc induces IMP1 transcrip-
tion by binding to the IMP1 promoter and is in turn stabi-
lized by the IMP1 protein (Bernstein et al. 1992; Prokipcak
et al. 1994; Doyle et al. 1998) in a positive feedback loop
analogous to that created by IMP1 and β-catenin.
The let-7 target HMGA2,which plays an important role
in the maintenance of pluripotency (for review, see Cley-
nen and Van de Ven 2008), has been shown to regulate
IMP2 gene expression (Cleynen et al. 2007). HMGA2
does not have intrinsic transcriptional activation capacity
but instead participates in the formation of higher-order
nucleoprotein complexes (enhanceosomes) in promoter/
enhancer regions of its target genes and is considered to
be an “architectural” transcription factor (Cleynen and
Van de Ven 2008; Pfannkuche et al. 2009). HMGA2 con-
tains three DNA-binding domains, called “AT hooks,”
whichrecognizeAT-rich regions inpromoters andenhanc-
ers to which they bind in a structure-specific rather than a
sequence-specific fashion. IMP2 possesses an AT-rich re-
gion in the DNA sequence encoding its first intron, which
is required for HMGA2-mediated regulation. Detailed as-
sessment of the sequences surrounding theHMGA2-bind-
ing region uncovered a consensus binding site forNF-kB in
the immediate vicinity of the AT-rich regulatory region.
NF-kBbinds to this site andcooperateswithHMGA2to in-
duce IMP2 expression (Cleynen et al. 2007).
Induction of IMP1 and IMP2 expression by c-Myc/β-cat-
enin and HMGA2, respectively, is consistent with both
normal and cancer stem cell (CSC) properties as well as
the oncofetal expression pattern of IMPs. Although the
mechanisms that underlie regulation of IMP expression
warrant further exploration, the observations that IMP1
and IMP2 are targets of central players in pluripotency
and oncogenesis are consistent with their requirement
in normal development and cancer initiation.
Implication in cancer: protection of let-7 target genes
and CSC maintenance
IMP family members are re-expressed in a broad range
of tumor types, where they appear to resume their
IMPs link normal and cancer stem cell maintenance
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physiological functions. By regulating the transport of cy-
toskeletal protein, adhesion receptor, and secretory pro-
tein mRNAs to the leading edge of motile cells and
stabilizing mRNAs of numerous oncogenes and pluri-
potency factors, IMPs may be predicted to participate
in several key events that underlie tumor development.
Consistent with this notion, transgenic mice engineered
to express IMP1 in mammary epithelial cells from the
whey acidic protein (WAP) promoter developedmammary
tumors in up to 95% of cases, some of which formed
metastases (Tessier et al. 2004).
These initial observations were supported by more re-
cent work in colorectal cancer (CRC) patients (Hamilton
et al. 2013), where increased IMP1 expression was found
to correlate with enhancedmetastasis and poor prognosis.
Accordingly, overexpression of IMP1 in CRC cell lines
promoted their ability to form tumors in immunocom-
promised mice and disseminate into the bloodstream
(Hamilton et al. 2013). Conversely, intestine-specific dele-
tion of Imp1 strongly reduced the number of tumors in
the ApcMin/+ model of intestinal tumor development,
and human CRC cell line xenografts depleted of IMP1 dis-
played reduced numbers of circulating tumor cells (CTCs)
(Hamilton et al. 2013). IMP1 overexpression decreased
E-cadherin expression in CRC cell lines and promoted
survival of CRC colonospheres as well as enrichment in
the CD44+CD24+ subpopulation associated with tumor-
initiating capacity (Hamilton et al. 2013).
Studies on IMP3,which is the IMP familymembermost
widely associated with human cancer (for review, see
Lederer et al. 2014), further support a functional implica-
tion of IMPs in tumor development. IMP3 expression was
first observed in PDACs (Gress et al. 1996) and was associ-
ated with up to 97% of invasive tumors (Yantiss et al.
2005). Its expression has been reported in most tumors
of the hepato-biliary system, including HCCs (Jeng et al.
2008; Hu et al. 2014), intrahepatic cholangiocarcinoma
(Chen et al. 2013b), gallbladder carcinomas (Shi et al.
2013), and bile duct carcinomas (Levy et al. 2010), where
it correlates with poor prognosis and invasiveness (Jeng
et al. 2008). IMP3 expression in HCC mouse models as
well as primary human HCC was observed to be highest
in CD133+/CD49f+ cells, which display CSC/tumor-initi-
ating cell (TIC) properties (Chen et al. 2013a), and has been
proposed to enhanceHCCcellmigration and invasiveness
by promoting the expression of HMGA2. Along with
IMP1, IMP3 is suggested to be among the most highly
up-regulated RBPs in HCC (Gutschner et al. 2014).
In breast carcinoma, IMP3 expression was observed to
be high in triple-negative tumors (TNBCs). Experiments
performed on cell lines suggest that IMP3 expression in
these tumors is repressed by estrogen receptor β (ERβ)
upon engagement by its ligand, 3βA-diol (Samanta et al.
2012), whereas it is induced by activation of the mito-
gen-activated protein kinase pathway in response to epi-
dermal growth factor receptor (EGFR) signaling. Based
on the discovery that ERβ represses EGFR transcription,
ERβ has been proposed to repress IMP3 indirectly as a
result of its effect on EGFR (Samanta et al. 2012). This
notion is consistent with TNBC biology, where low ERβ
levels allow elevated EGFR expression. IMP3 is suggested
to contribute to TNBC progression by stimulating inva-
sion and migration of the tumor cells, possibly as a result
of stabilizing MMP9 and CD164 (endolyn) transcripts
(Samanta et al. 2012). Depletion of IMP3 in TNBC cell
lines resulted in increased sensitivity to doxorubicin and
mitoxantrone (Samanta et al. 2013). The mechanism re-
sponsible for increased resistance to cytotoxic drugs was
found to be stabilization of breast cancer resistance pro-
tein (BRCP orABCG2) transcripts responsible for doxoru-
bicin andmitoxantrone efflux. IMP3was observed to bind
BCRP mRNA and thereby regulate protein expression,
although it is unclear whether the binding prevents
miRNA-mediated silencing. IMP3 has also been suggest-
ed to promote stemness in TNBCs based on the obser-
vation that it is more highly expressed in TICs than in
cells devoid of tumor-initiating capacity (Samanta et al.
2016). Investigation into the possible mechanisms under-
lying the putative induction or maintenance of stemness
by IMP3 in TNBC cells revealed that IMP3 binds to the
5′ UTR of SNAI2 (SLUG) mRNA and regulates its expres-
sion (Samanta et al. 2016). Stabilization of SLUG expres-
sion results in SOX2 up-regulation, which is implicated
in maintaining stemness (Samanta et al. 2016).
The observations in CRC, HCC, and TNBCs all point
toward a role for IMP1 and IMP3 in promoting or preserv-
ing tumor cell subpopulations with stem cell features and
thereby contributing to the establishment of tumor cell
hierarchies that are responsible for heterogeneity in a
broad range of tumors. Tumor cell heterogeneity, which
is a hallmark of solid tumors, can arise by several mecha-
nisms (for review, see Meacham and Morrison 2013). The
best established among these, which is referred to as clon-
al evolution, relies on intrinsic differences among cancer
cells resulting from stochastic genetic (Nowell 1976) and
epigenetic (Baylin and Jones 2011) changes that are subject
to selection within tumors. In some malignancies, how-
ever, nongenetic determinants related to developmental
pathways play a central role in tumor heterogeneity.
In these cancers, a small population of tumorigenic cells
has the unique capacity to generate nontumorigenic pro-
geny, which results in a hierarchical organization that
is a caricature of normal tissue architecture. Hemato-
poietic malignancies as well as a subset of solid tumors
have been shown to possess subpopulations of cells en-
dowed with stem cell properties that include expression
of ESC genes and asymmetric division (Lobo et al. 2007;
Kreso and Dick 2014). These cells also display tumor-
initiating capacity and are generally believed to represent
the tumor repopulating force, preserving their own num-
bers through self-renewal and generating more differen-
tiated progeny that comprises the bulk of the tumor.
Together, these properties functionally define CSCs.
Evidence from several laboratories provides a candidate
mechanism that underlies the association between IMP
expression and CSC-like phenotypes. All three IMP paral-
ogs have been shown to protect let-7 target genes from si-
lencing. They therefore fulfill a function similar to that of
LIN28A/B, albeit by distinct mechanisms, and may coop-
erate with LIN28A/B to induce or maintain stemness in
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tumor cells (Fig. 3). Similar to IMPs, LIN28 paralogs are
expressed in a broad range of tumor types, including
many pediatric malignancies (Carmel-Gross et al. 2016),
and predominantly in aggressive, poorly differentiated tu-
mor cell subpopulations (Viswanathan et al. 2009; Viswa-
nathan and Daley 2010; Shyh-Chang and Daley 2013).
LIN28 expression can be induced by numerousmediators,
one of which is NF-kB, the master regulator of the inflam-
matory response. NF-kB induces IL-6, which promotes
LIN28B expression and inhibition of let-7 maturation
(Iliopoulos et al. 2009), leading to increased expression of
several oncogenes and stemness maintenance genes that
may be relevant to the development of a cell hierarchy.
IMP family members are commonly re-expressed in tu-
mor cells that contain one or both of the LIN28 paralogs
(Busch et al. 2016; our unpublished observations). In
ovarian cancer cell lines, LIN28B and IMP1 appear to dis-
play synergistic protection of let-7 target transcripts, in-
cluding HMGA2, as well as mutual protection, as they
are both let-7 targets (Busch et al. 2016). Depletion of
both IMP1 and LIN28B in these cells decreases their
clonogenicity, migration, and tumor-initiating capacity
(Busch et al. 2016). Similar to its action in embryonic
cells, the mechanism by which IMP1 prevents let-7 tar-
get gene silencing in cancer cells appears to be by seques-
tration of its bound transcripts into mRNP granules
devoid of RISC/Ago (Fig. 2). IMP1 may therefore promote
CSC maintenance at least in part by preventing degrada-
tion of stemness and oncogene transcripts, including
LIN28B and HMGA2.
IMP3 may function in a way similar to that of IMP1,
sequesteringLIN28 andHMGA2mRNA into cytoplasmic
granules that do not contain RISC/Ago (Fig. 2; Jonson et al.
2014). However, IMP3may further promote CSC develop-
ment and maintenance by destabilizing mRNAs that en-
code proteins implicated in differentiation and/or tumor
suppression based on the discovery that IMP3 can recruit
AGO/RISC to some of itsmRNA targets (Ennajdaoui et al.
2016).
IMP2 has been less extensively studied in cancer, one
notable exception being GBM, where our group assessed
IMP2 mRNA binding by RIP-ChIP (Janiszewska et al.
2012) and, more recently, PAR-CLIP (Degrauwe et al.
2016). IMP2 expression was shown to be more elevated
in GSCs than in the tumor bulk, suggesting a possible
functional implication in GSC emergence and/or mainte-
nance. In GSCs, the expression of both let-7 family mem-
bers and their canonical target transcripts, including IMP2
itself, was observed in the absence of LIN28 paralogs, sug-
gesting that IMP2 expression alone may suffice to protect
let-7 target genes andmaintain stemness. Consistentwith
this notion, analysis of IMP2 binding to mRNA revealed
that IMP2 preferentially localizes to 3′ UTRs and binds
to a subset of MREs, including let-7 target sites (Fig. 2),
Figure 3. Schematic representation of the principal known functions of IMPs that may contribute to CSC properties and maintenance.
All three IMP paralogs as well as LIN28A/B block let-7 activity, albeit by differentmechanisms, and their transcripts are also let-7 targets.
Poorly differentiated tumor cells that display self-renewal and tumor-initiating properties express elevated levels of LIN28 paralogs, usu-
ally in conjunction with IMP family members, although some such cells express either LIN28 or IMP paralogs. Low let-7 levels facilitate
expression of LIN28, IMPs, andHMGA2. In addition, LIN28 and IMPs stabilize each others’ expression aswell as that ofHMGA2;HMGA2
in turn promotes expression of IMP2. Themain functions of IMPs recognized thus far that are associated with their elevated expression in
tumor cells include maintenance of stemness or pluripotency; transport of cytoskeletal and adhesion receptor mRNAs to the cell periph-
ery, which promote migration and invasiveness; enhancement of IGF2 translation; and transport of several nuclear-derived mRNAs that
encode various components of the respiratory chain to mitochondria, promoting oxidative phosphorylation (OXPHOS) .
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resulting in protection of the corresponding transcripts
from RISC/AGO-mediated silencing (Degrauwe et al.
2016).
As expected, LIN28B and IMP2were observed to engage
in the same functional pathway inGSCs. Thus, loss of clo-
nogenicity and tumor-initiating capacity by GSCs deplet-
ed of IMP2 was rescued by enforced LIN28B expression,
which led to a robust decrease in mature let-7 levels and
restoration of let-7 target gene expression. Depletion of
IMP2 alone, which does not affect let-7 biogenesis, did
not significantly alter mature let-7 expression.
Cooperation between LIN28 and dIMP has recently
been highlighted in neuroblast (NB)-derived tumors in
Drosophila melanogaster (Narbonne-Reveau et al. 2016).
Together with the transcription factor Chinmo, dIMP
and LIN28 form the core of an early oncogenic module
that controls Drosophila NB (dNB) mitotic activity and
that can be co-opted by susceptible cells to initiate malig-
nant growth during early larval development. Whereas
Chinmo behaves as an oncogene whose overexpression
in dNBs is sufficient to cause dNB amplification and initi-
ate tumor growth, dIMP appears to be required to sustain
tumor growth beyond developmental stages at least in
part by maintaining Chinmo expression. LIN28, which
is positively regulated by Chinmo in the tumors, appears
to be dispensable for tumor growth but may promote self-
renewal of Chinmo+/dIMP+ NBs and thereby increase tu-
mor growth potential. Coexpression of Chinmo, dIMP,
and LIN28 occurs in a small subset of dNBs,which sustain
unlimited tumor growth. Whether this subpopulation of
cells represents CSCs or a transient amplifying population
of progenitors derived from a distinct set of CSCs remains
to be determined. Themodel, however,may be relevant to
highly aggressive pediatric neural tumors that are often
initiated during early development (Narbonne-Reveau
et al. 2016).
Implication of IMP family members in functions relevant
to cancer other than stem cell maintenance
Several IMP functions that are not directly related to
maintenance of self-renewal and pluripotency may con-
tribute to IMP promotion of tumor growth and progres-
sion. Some of these may be related to interference with
miRNAs other than let-7 familymembers,whereas others
may be unrelated to miRNA activity. The transport of cy-
toskeletal and secretory protein mRNAs as well as stabi-
lization of cell adhesion receptor transcripts, including
CD44 and ITGB5, may be relevant to tumor progression.
IMP1 and IMP3 have been shown to enhance formation
of invadopodia (Vainer et al. 2008), and enforced expres-
sion of IMP1 promotes invasiveness of tumor cells in vitro
(for review, see Fig. 3; Bell et al. 2013). Consistent with
these observations, expression of IMPs was reported in
metastasizing CRCs and was observed to be particularly
high at the invasive edge (Vainer et al. 2008). However,
in another in vitro study, depletion of IMP1 in the breast
cancer cell lines T47D andMDA-MB231 enhancedmigra-
tion, whereas enforced expression of ZBP1 had the oppo-
site effect (Gu et al. 2008). In addition to β-actin mRNA,
IMP1 was observed to bind and transport mRNAs encod-
ing E-cadherin, α-actinin, and the Arp2/3 complex, which
are implicated in the stabilization of cell–cell contacts and
focal adhesions. Based on these findings, it would appear
that IMP1 may help maintain cell adhesion and polarity
and possibly diminish or even abolish chemotactic re-
sponsiveness (Lapidus et al. 2007). These seemingly con-
tradictory observations may reflect the breadth of IMP1
regulation of mRNA stability, with the capability of af-
fecting mRNAs that encode proteins implicated in oppos-
ing functions, including cell polarization, lamellipodia
formation, and migration (Lapidus et al. 2007; Vainer
et al. 2008). Cell context-specific events, such as the pres-
ence of other RBPs and miRNA expression repertoires
that modulate IMP1 activity, may help determine wheth-
er IMP1 preferentially promotes polarity or migration.
More recently, the loss of IMP3 was reported to reduce
PDAC invasiveness (Ennajdaoui et al. 2016). Numerous
IMP3 targets related to invasiveness and implicated in fo-
cal adhesions, adherens junctions, actin cytoskeleton, and
cell migration were identified by iCLIP in PDAC cells.
Which of these are stabilized by protection against
miRNA-mediated decay or destabilized as a result of
AGO/RISC recruitment remains to be determined (Ennaj-
daoui et al. 2016).
An important IMP function that may be implicated in
cancer development is the regulation of cell metabolism.
This appears to be a function preferentially associated
with IMP2, although it does not exclude participation of
other IMPs whose relationship to metabolism has not
been explored to the same depth. IMP2 was observed to
bind numerous nuclear-encoded mRNAs associated
withmitochondrial function (Vainer et al. 2008; Janiszew-
ska et al. 2012), and it is possible that IMP2 helps localize
the transcripts to mitochondria in a fashion analogous to
IMP1- and IMP3-mediated transport of cytoskeletal and
adhesion protein transcripts to the leading edge of motile
cells. Consistentwith this notion, IMP2was found to bind
mitochondria and regulate respiratory complex forma-
tion, favoring oxidative phosphorylation (OXPHOS) (Jan-
iszewska et al. 2012). Regulation of OXPHOS by IMP2
may provide an important contribution to GSC mainte-
nance (Fig. 3), as these cells appear to rely predominantly
on OXPHOS for their energy requirements. It will be im-
portant to determinewhetherOXPHOS is themechanism
of choice for energy provision by CSCs of other tumor
types.
An interesting observation is that the effect of IMPs on
tumor progression may differ according to whether they
are expressed in tumor cells or the tumor stroma. Thus,
loss of IMP1 expression in the stromahas been reported re-
cently to promote tumor growth in the azoxymethan
(AOM)/dextran sodium sulphate (DSS)model of colitis-as-
sociated cancer (Hamilton et al. 2015). IMP1-floxedmice
were crossed with DermoCre animals, resulting in IMP1
deletion in mesoderm-derived tissues, including fibro-
blasts, macrophages, and endothelial cells as of E9.5.
Loss of IMP1 in stromal cells did not appear to affect intes-
tinal homeostasis or the constitution of the intestinal
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stroma itself. However, mice lacking IMP1 in their stro-
mal cells developed a greater number of as well as larger
tumors in response to AOM/DSS than their wild-type
counterparts (Hamilton et al. 2015). The inflammation
provoked by AOM/DSS was more severe in mice lacking
IMP1 in their stromal cells, and inflammatory cell infil-
trates in the tumors were denser with stronger evidence
of a wound healing-type response. Candidate proposed
factors that may underlie the increased inflammation
and tissue remodeling include increased secretion of sev-
eral proinflammatory cytokines as well as Gremlin 1
(GREM1) and hepatocyte growth factor (HGF). HGF has
been implicated in CRC pathogenesis (Rasola et al.
2007) and is an important paracrine signaling component
in diverse cancer types. Pro-HGF and active HGFwere ob-
served to be increased in fibroblasts upon IMP1 depletion,
but the transcript level was unaffected, suggesting regula-
tion at the post-transcriptional/translational level (Hamil-
ton et al. 2015). The mechanisms by which GREM1 and
HGF are induced in response to inflammatory stimuli in
the context of IMP1 depletion remain to be elucidated,
but the observations suggest that expression of IMP1 in
the tumor microenvironment may play a restrictive role
in tumor growth.
IMP and LIN28 paralogs share multiple functions
LIN28 and IMP paralogs display intriguingly overlapping
functions at the pathophysiological level, albeit by dis-
tinctmolecularmechanisms that rely on different effector
complexes. A case in point is protection of let-7 target
genes, which appears to be a central function of both
LIN28 and IMP. Whereas IMPs sequester let-7 target tran-
scripts in RISC/Ago-free mRNP granules or disrupt let-7
binding to their recognition sites, LIN28 paralogs selec-
tively inhibit let-7 biogenesis by binding to the terminal
loop or pre-element (preE) of pre-let-7 and pri-let-7
and recruiting Zcchc11, a terminal uridylyl transferase
(TUTase; also known as TUT4). Zcchc11/TUT4 catalyzes
the addition of an oligo-uridine 3′ tail, which is a signal
for pre-let-7 degradation (Thornton and Gregory 2012).
By protecting let-7 target genes, both RBPs contribute
directly to CSC establishment and maintenance. Both
sets of paralogs are also let-7 targets and share many com-
mon target mRNAs. Moreover, they display several addi-
tional functional similarities that may be relevant to CSC
biology, some but probably not all of which are a conse-
quence of let-7 blockade.
LIN28A/B and IMPs display a temporally and spatially
similar expression pattern during normal development
(Christiansen et al. 2009; Balzer et al. 2010) and share
the ability to enhance translation of IGF-2 (Polesskaya
et al. 2007; Dai et al. 2011; Yang et al. 2015). They can
block glial differentiation (Balzer et al. 2010; Fujii et al.
2013) and are implicated in the control of cellular bioener-
getics (Janiszewska et al. 2012; Dai et al. 2015), and LIN28
is involved in the regulation of glucose metabolism (Zhu
et al. 2011) and in coordinating growth through let-7-de-
pendent regulation of numerous metabolic genes (Zhu
et al. 2011; Shyh-Chang and Daley 2013). LIN28 can also
enhanceOXPHOS duringwound healing through let-7-in-
dependent mechanisms, and inhibition of OXPHOS re-
duces its ability to promote tissue repair (Shyh-Chang
et al. 2013). These functions appear to be analogous to
those of IMP2-dependent promotion of OXPHOS in
GSCs, although the mechanisms and effector complexes
used may be distinct, as IMP2 regulation of respiratory
complex function requires physical interaction with mi-
tochondria (Janiszewska et al. 2012). Although the mech-
anisms by which IMP2 and LIN28 regulate cellular
bioenergetics require further elucidation, this particular
property shared by the two sets of paralogs may provide
an important contribution to tumor heterogeneity.
Are IMPs a part of a targetable CSC module?
There is compelling evidence to suggest that by regulating
let-7 biogenesis and mRNA targeting, respectively, the
LIN28 paralogs and the IMP family of RBPs provide key
players in determining the balance between pluripotency
maintenance and differentiation in cancer cell subpopula-
tions. LIN28A and LIN28B function upstream of IMPs to
regulate let-7 biogenesis, and, in their presence, mature
let-7 expression remains low, allowing cells to maintain
plasticity. In the absence of LIN28, IMPs may provide
the primary protection of let-7 target genes from silencing
by either sequestration into RISC/Ago-free compartments
(IMP1 and IMP3) or binding let-7 miRNA-binding sites in
3′ UTRs (IMP2), as observed in GSCs. Expression of both
LIN28 and IMPs may therefore appear redundant unless
IMPs provide a necessary fail-safemechanism for let-7 tar-
get gene preservation or complementary functions re-
quired for CSC function. One possibility is that, in the
presence of LIN28, IMPs may have a limited effect on
let-7 target gene maintenance but may tilt cellular bioen-
ergetics toward OXPHOS, which may be the preferred
mode of ATP generation in CSCs of at least some cancer
types and preserve relevant target genes of other miRNAs
to generate a proinvasive phenotype and contribute to
survival.
Implication of IMPs in CSC generation/maintenance
does not appear to be confined to any single tumor but
may be a general requirement for CSC maintenance irre-
spective of tumor type. This notion is supported by exper-
iments using TNBC, CRC, and HCC cell lines, which
have shown that IMP1/IMP3 play a role in promoting a
stem cell phenotype that includes resistance to cytotoxic
drugs and increased metastatic proclivity. In ovarian can-
cer, IMP1 appears to play the major role in promoting tu-
morigenesis along with LIN28B, whereas, in GBM, IMP2,
possibly with some participation of IMP3, ensures GSC
maintenance in the absence of LIN28 paralogs. Based on
the notion that expression of LIN28A/B and IMPs in can-
cer cells recapitulates developmental events, the expres-
sion levels and patterns of LIN28 and IMP paralogs may
reflect those of the corresponding embryonic cells and
provide clues as to the cell of origin of at least some tu-
mors. Careful assessment of expression of all LIN28 and
IMPs link normal and cancer stem cell maintenance
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IMP paralogs in tumor cell subpopulations, which is cur-
rently largely lacking, is thereforewarranted. From a func-
tional standpoint, it will be important to determine the
relative contribution of the different IMP paralogs to
CSC establishment and maintenance in different cancer
types and whether the presence of more than one paralog
serves merely as a backup or whether each paralog fulfills
distinct functions, possibly by targeting or protecting dif-
ferent mRNAs from degradation by distinct sets of miR-
NAs. Furthermore, different IMP paralogs may be
subject to distinct influences by other RBPs expressed in
a cell context-specific fashion, resulting in enhanced, sup-
pressed, or modified functions. Similarly, their functional
relationship to LIN28 paralogs remains to be clarified. In
other words, do IMPs and LIN28A/B have similar or dis-
tinct effects on self-renewal versus tumor-initiating ca-
pacity? In the presence of LIN28 and a low let-7
expression level, which IMP functions other than let-7
target gene protection contribute to the fine-tuning of
the CSC phenotype?Howmight they synergizewith anal-
ogous LIN28 functions to promote CSC/TIC properties?
Viewed from a different perspective, a central and per-
haps essential event in CSC maintenance in diverse can-
cer types appears to be keeping let-7 family member
expression and function in check, as is the case in ESC/
progenitor cell maintenance during normal development.
The fact that control of let-7 expression relies on at least
three distinct mechanisms—biogenesis blockade by the
LIN28 paralogs, protection of target mRNAs by IMP fam-
ily members, and sequestration of mature let-7 forms by
H19 and possibly other transcripts, which remove let-7
by providing a sponge effect (Kallen et al. 2013)—testifies
to the importance of let-7 in regulating the switch be-
tween stemness and differentiation. Reactivation of
such a central developmental switch underscores the sim-
ilarity between cellular hierarchies in normally develop-
ing tissues and cancer and suggests that IMP family
members along with LIN28 paralogs may provide core
components of a CSC determination and maintenance
module. If so, they or their regulatory circuits may be-
come prime therapeutic targets whose neutralization
may be effective in blunting the driving force of a broad
range of malignancies, particularly solid tumors whose
treatment remains a major challenge.
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